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Summary
Objective: The aim of the present study is that of characterizing, for the ﬁrst time in a quantitative way, from a biochemical, physico chemical
and functional point of view P2X1 and P2X3 purinergic receptors in bovine chondrocytes. The afﬁnity and the potency of typical purinergic
ligands were studied through competition binding experiments and their role in modulating chondrocyte actvities was investigated by analyzing
nitric oxide (NO) and prostaglandin E2 (PGE2) release.
Methods: Saturation, competition binding experiments, western blotting and immunohistochemistry assays on the P2X1 and P2X3 purinergic
receptors in bovine chondrocytes were performed. Thermodynamic analysis of the P2X1 and P2X3 purinergic binding was studied to inves-
tigate the forces driving drug-receptor coupling. In the functional assays (NO and PGE2 release) the potency of purinergic agonists and an-
tagonists was evaluated.
Results: Bovine chondrocytes expressed P2X1 and P2X3 purinergic receptors and thermodynamic parameters indicated that purinergic bind-
ing is enthalpy- and entropy-driven for agonists and totally entropy-driven for antagonists. Typical purinergic agonists such as adenosine
50-triphosphate (ATP) and a,b-methyleneATP were able to increase NO and PGE2 release. A purinergic antagonist, A317491, was able to
block the stimulatory effect on functional experiments mediated by the agonists.
Conclusions: These data demonstrate for the ﬁrst time the presence of functional P2X1 and P2X3 purinergic receptors in bovine chondrocytes.
Agonists and antagonists are thermodynamically discriminated and are able to modulate functional responses such as NO and PGE2 release.
These results suggest the potential role of novel purinergic antagonists in the treatment of pathophysiological diseases linked to the inﬂam-
mation and involved in articular cartilage resorption.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chondrocytes within articular cartilage are responsible for
the synthesis and degradation of the extracellular matrix,
which in healthy tissue provide mechanical functionality.
In degenerative diseases such as osteoarthritis and rheu-
matoid arthritis there is a net loss of cartilage because the
rate of catabolism exceeds the rate of synthesis and depo-
sition of the macromolecular components of the extracellu-
lar matrix1. Several chondrocyte activities are associated to
cartilage damage, and include the up-regulation of nitric ox-
ide (NO) and lipid inﬂammatory mediators such as prosta-
glandins (PGE), as well as the increased production of
matrix-degrading enzymes2.
Growing evidence suggests that extracellular nucleo-
tides, might play important roles in the regulation of carti-
lage metabolism3,4. Extracellular nucleotides have been
shown to enhance growth factor-induced proliferation of
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142150-triphosphate (ATP) and adenosine diphosphate (ADP)
can stimulate the production of cartilage inﬂammatory medi-
ators such as PGE by cultured human chondrocytes, which
is enhanced by the pro-inﬂammatory cytokines interleukin
1-b (IL-1b), interleukin 1-a (IL-1a) and tumor necrosis factor
a (TNF-a)6e8. ATP can promote cartilage resorption through
the breakdown of proteoglycans and the release of glycos-
aminoglycans1,9. On the other hand, it has been also re-
ported that the release of ATP and the activation of
purinergic pathways induced by physiological mechanical
stimulation can be involved in beneﬁcial effects on cartilage,
including the up-regulation of proteoglycan synthesis and
the downregulation of inﬂammatory mediators such as
NO10e14. These previous studies indicate the involvement
of purinergic pathways in the modulation of cartilage metab-
olism, however, to date, the pharmacological characteriza-
tion of purinergic receptors and the effects of nucleotides
in chondrocytes have not been investigated in detail. Sev-
eral pharmacological studies on transduction mechanisms
and molecular biology indicate the basis for subdivision of
P2 receptors into P2X and P2Y families15,16. In particular,
seven subtypes of P2X receptors and eight subtypes of
P2Y receptors are currently recognized17. P2X purinergic
receptors are membrane ligand-gated ion channels that
open in response to the binding of extracellular ATP which
represents an important local regulatory factor of the
1422 K. Varani et al.: Purinergic receptors in bovine chondrocytesinﬂammatory response. P2X receptors are abundantly dis-
tributed and functional responses have been described in
neurons, glia, epithelia, endotelia, bone, muscle and hemo-
poietic tissues15.
Over the last few years attempts to characterize endoge-
nous and recombinant P2X purinergic receptors using
radioligand binding techniques have had limited success,
primarily due to a lack of selective radioligands15,18. The
availability of [3H]-a,b-methyleneATP as a selective radioli-
gand to study P2X purinoceptors presents a very good tool
for determining the distribution of these receptors and their
binding parameters19. In addition, to better characterize the
ligandereceptor interaction a thermodynamic analysis of
human P2X1 and P2X3 purinergic receptors expressed in
HEK293 cells has been performed20. Numerous thermody-
namic studies have reported that the discrimination of the
agonists and antagonists occur in different classes of mem-
brane or intracellular receptors conﬁrming the important role
of the thermodynamic parameters to clarify the mechanisms
of ligandereceptor binding21e25.
From the current background, the aim of this study was to
investigate the presence of P2X receptors in bovine chon-
drocyte membranes by using western blotting, immunohis-
tochemistry and saturation binding assays. Competition
binding experiments and thermodynamic analysis with typ-
ical purinergic ligands were also performed to characterize,
from a pharmacological point of view, P2X purinergic recep-
tors expressed in bovine chondrocytes. The capabilities of
the same purinergic ligands to modulate chondrocyte cata-
bolic activities were evaluated by analyzing the effects on
NO release and PGE2 production, both in the absence
and in the presence of IL-1. This paper could be helpful in
the development of new P2X1 and/or P2X3 purinergic an-
tagonists, possible drugs for the treatment of inﬂammatory
processes involved in articular diseases.Materials and methodsHUMAN P2X1 AND P2X3 PURINERGIC RECEPTORS
EXPRESSED IN HEK293 CELL CULTURE AND MEMBRANE
PREPARATIONHEK293-hP2X1 and HEK293-hP2X3 cells were kindly provided by
Proffessor A. Surprenant (Institute ofMolecular Physiology, University of Shef-
ﬁeld, Shefﬁeld, England, UK). In particular, HEK293-hP2X1 and HEK293-
hP2X3 cells were generated by transformation of human embryonic kidney
cell cultures and stably expressed purinergic receptors26. These cells were
grown adherently and maintained in Dulbecco’s Modiﬁed Eagle’s Medium
with nutrient mixture F12 (DMEM/F12), containing 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 mg/ml) and Geneticin (G418, 0.2 mg/
ml) at 37C in 5% CO2/95% air. For membrane preparation, the culture
medium was removed, the cells were washed with phosphate buffered saline
(PBS)andscraped in ice-coldhypotonicbuffer (5-mMTriseHCl,2-mMethylene
diamine tetraacetic acid (EDTA), pH 7.4). The cell suspension was homoge-
nized and centrifuged for 30 min at 100,000 g. The membrane pellet was re-
suspended in 50-mM TriseHCl, 4-mM CaCl2, pH 7.4 and frozen at 80C.CHONDROCYTE CULTURE AND MEMBRANE PREPARATIONBovine articular cartilage derived from the metacarpophalangeal joints of
14e18 month-old animals (Limousin breed). Chondrocytes were isolated
from cartilage fragments obtained from the weight-bearing region of the artic-
ular surface27,28. Brieﬂy, the cartilage was dissected out and cut into small
pieces that were subjected to a sequential digestion in DMEM/F12 (1:1)
medium (GibcoeInvitrogen, Paisley, UK) with pronase from Streptomyces gri-
seus (Calbiochem, Darmstadt, Germany) for 90 min and collagenase P from
Clostridium histolyticum (Roche, Indianapolis, USA) for 12 h. The resulting
suspension was ﬁltered to remove undigested cartilage and chondrocytes
were recovered by centrifugation, counted and plated at high density
(150,000/cm2) in 75-cm2 ﬂasks and in multiwells (1.6 cm the diameter of
each well). Chondrocytes were cultured in DMEM/F12 supplemented with
10% fetal bovine serum (FBS) and antibiotics (penicillin 100 U/ml, streptomy-
cin 0.1 mg/ml) (GibcoeInvitrogen, Paisley, UK). Only chondrocytes withoutsubculturing and maintained in culture for 1 week were used in the binding
and functional experiments. In chondrocyte cultures the presence of aggrecan
and type II collagen and the absence of type I collagen were shown by immu-
nohistochemistry indicating the maintenance of the chondrocyte phenotype29.
For membrane preparation, the culture medium was removed and the
cells were washed with PBS and scraped off T75 ﬂasks in ice-cold hypotonic
buffer (5-mM TriseHCl, 2-mM EDTA, pH 7.4). The cell suspension was
homogenized, centrifuged for 30 min at 100,000 g and used in saturation
and competition binding experiments.WESTERN BLOTTING ANALYSIS FOR P2X1 AND P2X3
RECEPTORSBovine chondrocytes (n¼ 3) in comparison with HEK293-hP2X1 (n¼ 3)
and HEK293-hP2X3 (n¼ 3) cells were harvested and washed with ice-cold
PBS containing 1-mM sodium orthovanadate, 104-mM 4-(2-aminoethyl)-
benzenesulfonyl ﬂuoride, 0.08-mM aprotinin, 2-mM leupeptin, 4-mM bestatin,
1.5-mM pepstatin A, 1.4-mM E-64. Then cells were lysed in Triton lysis buffer
and the protein concentration was determined using bicinchoninic acid (BCA)
protein assay kit (Pierce). Aliquots of total protein sample (50 mg) were ana-
lyzed using polyclonal antibodies for human P2X1 and P2X3 purinergic
receptors (Neuromics Antibodies, 1 mg/ml dilution) and for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Novus Biologicals)30. Filters were
washed and incubated for 1 h at room temperature with peroxidase-conjugated
secondary antibodies (1:2000 dilution). Speciﬁc reactions were revealed with
Enhanced Chemiluminescence Western blotting detection reagent (Amersham
Biosciences).IMMUNOHISTOCHEMISTRY FOR P2X1 AND P2X3 RECEPTORSThe expression of P2X1 and P2X3 receptors was also evaluated by immu-
nohistochemistry in cartilage fragments immediately after dissection from the
articular surface31. Brieﬂy, cartilage fragments were ﬁxed in freshly prepared
4% paraformaldehyde (PFA) w/v in PBS, pH 7.2 for 3 h and then transferred
to 10% sucrose in PBS and refrigerated overnight. The samples were
embedded in optimum cutting temperatures medium and 4e5-mm thickness
sections were cut using a cryostat and collected onto clean glass superfrost
slides. After washing in PBS, endogenous peroxidase was blocked by incu-
bation with 0.3% w/v hydrogen peroxide in methanol. After a further wash in
PBS, the tissue sections were incubated with polyclonal rabbit antibodies to
P2X1 and P2X3 receptors (Neuromics Antibodies, 1:500) overnight. Stain
was obtained by developing with ultraystain polyvalent horseradish peroxi-
dase (HRP) immunostaining kit (Ylem, Rome, Italy), using the procedure rec-
ommended by the manufacturer. Negative controls were prepared without
primary antibody and nuclei were counterstained by hematoxylin.SATURATION AND COMPETITION BINDING ASSAYSSaturation binding experiments of [3H]-a,b-methyleneATP (speciﬁc activ-
ity 15.0 Ci mmol1, NEN-Perkin Elmer Life and Analytical Sciences, USA)
(from 0.1 to 50 nM) to the membranes previously obtained (100 mg of pro-
tein/assay) were performed by incubating from 40 min at 5C to 90 min at
30C according to the results of previous time-course experiments.
Competition experiments of 3-nM [3H]-a,b-methyleneATP were performed
in duplicate in test tubes containing 50-mM TriseHCl, 4-mM CaCl2 buffer,
100 ml of membranes and at least 8e10 different concentrations of P2X1
and P2X3 agonists or antagonists studied. ATP, ADP, a,b-methyleneATP,
BenzoilATP, TNP-ATP, suramin, NF023, PPADS, A317491 were obtained
from Sigma-Aldrich Advanced Sciences (Milan, Italy). NF279 and 2-
methylSATP were obtained from Tocris Cookson Ltd (Bristol, UK).
Non speciﬁc binding was determined in the presence of 10-mM a,b-
methyleneATP32. Bound and free radioactivity were separated by rapid ﬁltra-
tion throughWhatman GF/B glass-ﬁber ﬁlters using a Brandel instrument. The
ﬁlter bound radioactivity was counted on a Scintillation Counter Tri Carb Pack-
ard 2500 TR (efﬁciency 57%). The protein concentration was determined
according to a Bio-Rad method with bovine albumin as reference standard33.THERMODYNAMIC DATA DETERMINATIONFor a generic binding equilibrium LþR¼ LR (L¼ ligand, R¼ receptor)
the afﬁnity association constant KA¼ 1/KD is directly related to the standard
free energy DG (DG ¼ RT ln KA) which can be separated in its enthalpic
and entropic contributions according to the Gibbs equation: DG ¼
DH  TDS. The standard free energy was calculated as DG ¼RT ln KA
at 298.15 K, the standard enthalpy, DH , from the van’t Hoff plot ln KA vs
(1/T ) (the slope of which is DH/R) and the standard entropy as
DS ¼ (DH DG)/T with T¼ 298.15 K and R¼ 8.314 J/K/mol24. KA values
were obtained from [3H]-a,b-methyleneATP saturation experiments in bovine
chondrocyte membranes carried out at 0, 10, 15, 20, 25 and 30C in a ther-
mostatic bath assuring a temperature of 0.1C.
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Fig. 1. Western blotting analysis of bovine chondrocytes for puriner-
gic receptors in comparison with HEK293-hP2X1 and HEK293-In functional assays including the analysis of PGE2 and NO release,
chondrocytes isolated from cartilage, plated at high density (150,000/cm2)
in multiwells and maintained in culture for 1 week were used. At the begin-
ning of the experiments (time 0), medium was changed in all cultures. To
test the effects of purinergic agonists cells were incubated in complete
medium containing increasing doses of ATP (10, 100, 500 mM) and a,b-
methyleneATP (1, 10, 100 mM).
In a second series of experiments ATP (10, 100, 500 mM) and a,b-
methyleneATP (1, 10, 100 mM) were added to medium containing 50-ng/ml
Recombinant Human IL-1b (Preprotech INC, Rocky Hill, NJ, USA), used to
activate inﬂammatory activities in chondrocytes2. To evaluate the capability
of A317491 to antagonize the effects of the purinergic agonists, 1 mM of
this antagonist was added to the treated cultures. All treatments were
made up in triplicate wells for 24 h. At the end of treatment, the culture
medium was removed from the wells and stored at 80C for subsequent
determination of PGE2 and NO release. The monolayers were solubilized
in sodium hydroxide and protein concentration was evaluated33.hP2X3 cells. GAPDH was used as the loading control.NO ASSAYThe release of nitrite, a stable breakdown product of NO was measured
as an indicator of NO synthesis. At the end of the 24 h of treatment period,
nitrite concentration was determined in the conditioned media according to
Greiss method34. Brieﬂy, culture medium was mixed with an equal volume
of the Greiss reagent and absorbance was measured at 550 nm. Nitrite
concentration was calculated from a standard curve of sodium nitrite.PGE2 ASSAYThe concentration of PGE2 was measured using a commercially available
competitive enzyme immunoassay (PGE2 ASSAY, R&D Systems, Inc., MN,
USA). Brieﬂy, medium was diluted threefold in Calibrator Diluent (RD5-39)
included in the kit and 100 ml of diluted sample or standard were added to
each well of a microplate coated with goat antimouse antibody. Subse-
quently, horseradish peroxidase (HRP)-labeled PGE2 and a mouse mono-
clonal antibody to PGE2 were added to each well and the plate was
incubated for 2 h and washed. The substrate solution was added to each
well and following 30-min incubation a stop solution containing phosphoric
acid was added to each well and the absorbance was measured at
450 nm with a reference of 570 nm. All samples and standards were assayed
in duplicate. PGE2 production was normalized to the total protein content and
expressed as picogram (pg) PGE2/mg protein.STATISTICAL ANALYSISA weighted non linear least-squares curve ﬁtting program Ligand35 was
used for computer analysis of saturation and competition binding experiments.
Functional experiments were calculated by non linear regression analysis us-
ing the equation for a sigmoid concentration response curve (GraphPAD
Prism, San Diego, CA, USA). Analysis of data was done with Student’s t test
(unpaired analysis). Differences were considered signiﬁcant at a value of
P< 0.01. All data are reported as mean standard error of the mean
(S.E.M.) of independent experiments (n¼ 3e4 as indicated in ﬁgure legends).ResultsWESTERN BLOTTINGFigure 1 shows the immunoblot signals of P2X1 and P2X3
purinergic receptors in bovine chondrocytes in comparison
with HEK293-hP2X1 and HEK293-hP2X3 cells. P2X1 and
P2X3 purinergic receptors are present in bovine chondro-
cytes showing a minor expression than in HEK293-hP2X1
and HEK293-hP2X3 cells
20. In addition, in bovine chondro-
cytes P2X1 receptor expression resulted lower than P2X3
receptor. Figure 1 also reports the immunoblot signals of
GAPDH used as loading control.IMMUNOHISTOCHEMISTRY
Fig. 2. Immunohistochemistry of P2X3 receptors (A) and P2X1 re-
ceptors (B) in cartilage sections. In (B) nuclei are counterstained
by hematoxylin.The immunohistochemistry of purinergic receptors in car-
tilage slices showed that chondrocytes in all zones of thearticular cartilage stained positive for P2X3 receptors con-
ﬁrming the expression of the receptor in intact cartilage
[Fig. 2(A)]. No signal for P2X1 receptors was observed in
cartilage slices [Fig. 2(B)]. Negative controls, obtained with-
out primary antibodies, did not show any staining.
Table I
Binding parameters, expressed as KD and Bmax values, of [
3H]-a,b-methyleneATP in bovine chondrocyte membranes
[3H]-a,b-methylene ATP binding 5(C (278 K) 10(C (283 K) 15(C (288 K) 20(C (293 K) 25(C (298 K) 30(C (303 K)
KD (nM) 3.3 0.3 4.3 0.4 5.5 0.5 6.6 0.6 7.5 0.7 8.4 0.7
Bmax (fmol/mg protein) 4900 420 4950 440 5050 480 5000 470 4800 450 4750 490
Dissociation constants (KD, nM) and Bmax values (fmol/mg protein) are referred to the binding of [
3H]-a,b-methyleneATP to purinergic re-
ceptors in bovine chondrocytes. Data are expressed as the mean S.E.M. obtained from at least four independent experiments performed in
duplicate.
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were performed to evaluate afﬁnity (KD) and receptor den-
sity (Bmax) values of P2X purinergic receptors (Table I,
Fig. 3). The binding parameters were determined at various
temperatures (0, 10, 15, 20, 25 and 30C) by using [3H]-a,b-
methyleneATP as radioligand at different concentrations.
These results demonstrate that KD values change with tem-
perature and Bmax values appear to be largely independent
of it. Computer analysis of the data failed to show a signiﬁ-
cantly better ﬁt to a two site than to a one site binding
model, indicating that only one class of high afﬁnity binding
site is present under our experimental conditions. Figure 4
shows the dose response curves of [3H]-a,b-methyleneATP
binding in bovine chondrocyte membranes by using
typical agonists and antagonists (Table II). The order of
potency in [3H]-a,b-methyleneATP displacement assays0 10 20 30 40 50
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Fig. 3. Saturation of [3H]abmeATP binding to P2X purinergic recep-
tors in bovine chondrocytes at 5C and 25C (A). Experiments were
performed as described in Materials and methods. Values are the
means and vertical lines S.E.M. of four separate experiments per-
formed in triplicate. The Scatchard plots of the same data are
shown in the panel B.for purinergic agonists was as follow: a,b-methyleneATP>
BenzoilATP 2-methylSATPATP> ADP. Similarly, the
order of potency of antagonists in bovine chondrocyte mem-
branes was as follow: TNP-ATP> A317491>Suramin>
NF023>NF279>PPADS.THERMODYNAMIC ANALYSISThe van’t Hoff plots show that the effect of temperature
on the equilibrium binding association constants, KA ap-
pears to be essentially linear in the range 4e30C for the
purinergic ligands examined (Fig. 5). Final thermodynamic
parameters (expressed as mean values standard error
of four independent experiments) calculated for the binding
equilibria of the different compounds investigated are re-
ported in Table III.
Thermodynamic parameters of bovine chondrocytes for
agonists show an enthalpy- and entropy-driven binding
and the antagonist binding was totally entropy-driven.-10 -9 -8 -7 -6 -5 -4 -3 -2
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Fig. 4. Competition curves of typical purinergic agonists (A) and an-
tagonists (B) in bovine chondrocytes. Competition experiments
(n¼ 4) were performed as described in Materials and methods.
Table II
Affinities, expressed as Ki values (nM), of selected purinergic agonists and antagonists in bovine chondrocyte membranes at different
temperatures
Ligand 5(C, 278 K 10(C, 283 K 15(C, 288 K 20(C, 293 K 25(C, 298 K 30(C, 303 K
Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM)
Purinergic agonists
ATP 90 8 120 11 137 15 168 17 200 19 250 22
ADP 120 9 150 12 186 17 205 18 250 20 306 28
a,b-methyleneATP 3.0 0.3 4.1 0.3 5.0 0.4 6.1 0.5 6.9 0.6 8.1 0.7
2-methylSATP 85 8 110 10 130 12 150 15 185 20 220 22
BenzoilATP 80 7 100 9 124 13 145 14 170 16 205 21
Purinergic antagonists
Suramin 9000 850 8000 750 7000 650 6500 550 5500 450 5000 400
NF023 11 000 850 10 000 850 9000 850 8500 850 7500 850 6000 850
TNP-ATP 100 10 135 15 150 16 180 18 230 25 280 20
PPADS 25 000 2200 21 000 2000 18 000 1700 12 000 1000 10 000 900 9000 800
A31749 950 85 800 70 750 60 600 60 550 50 450 40
NF279 15 000 1400 13 000 1300 12 500 1200 11 000 1100 9500 900 8000 700
Data are expressed as the mean S.E.M. of four independent experiments performed in duplicate.
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experiments reported to be a purinergic antagonist36 shows
a typical agonist behavior with an afﬁnity value and thermo-
dynamic parameters strictly similar to those obtained
from other purinergic agonists. Figure 6(A) reports the
van’t Hoff plot and thermodynamic parameters of the3.2 3.3 3.4 3.5 3.6 3.7 3.8
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Fig. 5. Van’t Hoff plot in bovine chondrocytes showing the effect of
temperature on the equilibrium binding association constant, KA, for
P2X purinergic agonists (A) and antagonists (B). The plots are es-
sentially linear in the temperature range investigated (5e30C).
Binding experiments were performed as described in Materials
and methods (n¼ 4).[3H]-a,b-methyleneATP radioligand showing that this bind-
ing was enthalpy- and entropy-driven. Figure 6(B) summa-
rizes the results obtained in bovine chondrocytes in the
form of TDS  vs DH  scatter plot (T¼ 298.15 K) and
shows that purinergic antagonists are clustered in the endo-
thermic region (15DH   30 kJ mol1) with large positive
entropy values (58.11TDS  44.40 kJ mol1) re-
vealing that their binding is totally entropy-driven. Agonistic
binding was enthalpy- and entropy-driven (26DH  
24 kJ mol1 and 20.26TDS  11.62 kJmol1)
suggesting that agonists and antagonists in bovine chondro-
cytes are discriminated from a thermodynamic point of view.EFFECTS OF PURINERGIC LIGANDS ON NO PRODUCTION
IN CHONDROCYTE MONOLAYERSFigure 7 illustrates the effects of ATP and a,b-methyle-
neATP on NO production in bovine chondrocytes in basal
condition [Fig. 7(A)] and after IL-1b treatment [Fig. 7(B)]. In
the absence of IL-1b, treatment of cells with 500-mM ATP
and 100-mM a,b-methyleneATP induced a low but
signiﬁcant increase on basal NO production [Fig. 7(A)]. In
the same experimental conditions described above, ATPTable III
Thermodynamic parameters for the binding equilibrium of [3H]-a,b-
methyleneATP to bovine chondrocyte membranes of selected puri-
nergic agonists and antagonists
Ligand DG(
(kJ mol1)
DH(
(kJ mol1)
DS(
(J/mol/K)
Purinergic agonists
ATP 38.0 3.8 26 2 39 2
ADP 37.5 3.7 24 1 44 3
a,b-methyleneATP 46.4 4.1 26 2 68 3
2-methylSATP 38.2 3.4 25 1 45 4
BenzoilATP 38.4 3.6 25 2 46 2
Purinergic antagonists
Suramin 30.0 3.0 16 1 155 5
NF023 29.2 2.9 15 1 149 5
TNP-ATP 37.7 3.5 27 2 38 3
PPADS 21 2.0 30 2 195 8
A31749 35.6 3.4 19 1 184 7
NF279 28.6 2.8 16 0 150 5
Thermodynamic parameters, DG(, DH( and DS( values, are
given at 278 K.
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Fig. 7. Effect of purinergic ligands in the absence (A) and in the
presence (B) of IL-1b on NO release in bovine chondrocytes
(n¼ 3; **P< 0.01 vs Control; #P< 0.01 vs IL-1b 50 ng/ml).
1426 K. Varani et al.: Purinergic receptors in bovine chondrocytesuntil 100-mM concentration and a,b-methyleneATP until 10-
mM concentration were not able to modulate NO release. In
the presence of IL-1b [Fig. 7(B)], both ATP and a,b-
methyleneATP induced a dose-dependent increase on
NO production, ranging from 11 to 84% with respect to
IL-1b-treated cells. The purinergic antagonist A317491
efﬁciently counteracted the activity of both ATP and a,b-
methyleneATP inhibiting NO production to the levels of
cells treated with IL-1b alone.EFFECTS OF PURINERGIC LIGANDS ON PGE2 PRODUCTION IN
CHONDROCYTE MONOLAYERSFigure 8 shows the effects of ATP and a,b-methyleneATP
on PGE2 production in bovine chondrocytes in basal condi-
tion [Fig. 8(A)] and after IL-1b treatment [Fig. 8(B)]. In the
absence of IL-1b, treatment of cells with ATP in the range
of concentrations from 10 to 500 mM and a,b-methyleneATP
(10 and 100 mM) induced a signiﬁcant increase on basal
PGE2 production [Fig. 8(A)]. In the same experimental con-
ditions described above, 1 mM of a,b-methyleneATP was
not able to modulate PGE2 release. In the presence of IL-
1b, both ATP (500 mM) and a,b-methyleneATP (100 mM)induced a maximum increase on PGE2 production, of
137e79%, respectively. ATP at the 100-mM concentration
was able to induce slightly but signiﬁcant PGE2 release
[P< 0.05; Fig. 8(B)]. The purinergic antagonist A317491
counteracted in a different way the activity of both ATP
and a,b-methyleneATP [Fig. 8(B)]. In particular, A317491
partially reduced ATP-mediated PGE2 release whilst it
completely inhibited a,b-methyleneATP-mediated PGE2
release.Discussion
The purpose of the current investigation was to document
the expression, the binding parameters and the functionality
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Fig. 8. Effect of purinergic ligands in the absence (A) and in the
presence (B) of IL-1b on PGE2 release in bovine chondrocytes
(n¼ 3; **P< 0.01 vs Control; *P< 0.05 vs Control; #P< 0.01 vs
IL-1b 50 ng/ml; xP< 0.05 vs IL-1b 50 ng/ml).
1427Osteoarthritis and Cartilage Vol. 16, No. 11of P2X purinergic receptor subtypes in bovine chon-
drocytes. The presence of purinergic receptors was
investigated through western blotting analysis, immunohis-
tochemistry and saturation binding experiments. Western
blotting assays reveal the presence of P2X1 and P2X3 pu-
rinergic receptors as reported in Fig. 1 where bovine chon-
drocytes were analyzed in comparison with HEK293-hP2X1
and HEK293-hP2X3 cells. In both cell types, P2X3 puriner-
gic receptors were present at higher level than P2X1
purinergic receptors. Immunohistochemistry in cartilage
slices conﬁrmed the presence of P2X3 purinergic receptors
while P2X1 purinergic receptors were not detectable proba-
bly due to the low presence of these receptors in this sub-
strate. Another possible hypothesis could be that P2X1purinergic expression was induced by the in vitro culture
conditions. Purinergic receptors were also characterized
in saturation binding experiments showing the presence
of an high afﬁnity binding site with a KD of 3.3 0.3 nM
and a receptor density (Bmax) of 4900 420 fmol/mg
protein. In addition, thermodynamic parameters obtained
from the van’t Hoff plot indicate that [3H]-a,b-methyleneATP
binding to purinergic receptors is enthalpy- and entropy-
driven, with a major contribution of the enthalpic compo-
nent. The information provided by these data could be
useful from a pharmacological point of view to discover
new thermodynamic relationships linked to ligandereceptor
interactions useful to the development of new potential
classes of drugs37e42.
From the competition binding experiments, performed with
the aim to calculate the afﬁnity of the agonists for purinergic
receptors, the order of potency was a,b-methyleneATP>
BenzoilATP 2-methylSATPATP> ADP. The same
order of potency was reported at all the temperatures inves-
tigated even if the afﬁnity values of the purinergic com-
pounds decreased with the increase of the temperature.
The order of potency of the studied purinergic antagonists
was TNP-ATP> A31749> Suramin>NF023>NF279>
PPADS. Similarly, the order of potency was the same from
5C to 30C even if the afﬁnities of the antagonists increased
(Ki decreased) with the increase of the temperature. More-
over, in our experimental conditions, purinergic agonists
revealed a higher afﬁnity, in the nanomolar range, when
compared to purinergic antagonists that showed an afﬁnity
in the low nanomolaremicromolar range. In addition a,b-
methyleneATP was the most afﬁne and potent agonist
showing an high afﬁnity in the nanomolar range. On the con-
trary ATP, a typical purinergic endogenous ligand, revealed
a lower afﬁnity than a,b-methyleneATP vs P2X purinergic
receptors. Collectively, these binding data of afﬁnity are
important to identify the speciﬁc concentrations of agonists
and antagonists to use in functional and molecular in vitro
and in vivo experiments.
Another purpose of the present study was to investigate
from a functional point of view the purinergic P2X receptors
in bovine chondrocytes. To this aim, the effects of ATP and
a,b-methyleneATP on NO production and PGE2 release
were analyzed. Both NO and PGE2 are synthesized by
chondrocytes43, and have been implicated as critical inﬂam-
matory mediators of cartilage matrix degradation44e47. ATP
and a,b-methyleneATP were able to increase NO produc-
tion at micromolar concentration similarly to that reported
in literature1,6 and the P2X antagonist A317491 was able
to decrease the stimulatory effect mediated by the puriner-
gic agonists investigated. It is well known that IL-1b, a pro-
inﬂammatory agent which is present in elevated amount in
osteoarthritic cartilage and plays a decisive role in osteoar-
thritis, also increases the production of NO44. In agreement
the treatment of bovine chondrocytes with 50 ng/ml of IL-1b
signiﬁcantly increased NO synthesis. Interestingly, ATP and
a,b-methyleneATP were able to further stimulate the pro-
duction of NO in a dose-dependent manner and A317491
completely inhibited the stimulatory effect mediated by the
purinergic agonists. The similar behavior of ATP and a,b-
methyleneATP and the complete inhibition of their effects
by A317491 indicate the involvement of P2X receptors in
the stimulation of NO release. In addition, ATP and a,b-
methyleneATP stimulated the production of PGE2 in
a dose-dependent manner, both in the absence and in the
presence of IL-1b, indicating a role for P2X in PGE2 release.
Interestingly, ATP had an higher effect than a,b-methyl-
eneATP and A317491 was able only to partially inhibit
1428 K. Varani et al.: Purinergic receptors in bovine chondrocytesthe effect of ATP and to completely decrease the effect of
a,b-methyleneATP. These differences are probably due to
the presence of P2Y receptors, involved in PGE2 re-
lease16, which can be activated by ATP but not by a,b-
methyleneATP. The results of this paper conﬁrm ATP as
an important extracellular signal involved in cartilage
metabolism and indicate that the stimulation of purinergic
pathways, mediated by P2X receptors, can increase the in-
ﬂammation process associated to cartilage pathological
conditions. On the other hand, studies concerning physio-
logical mechanical stimulation on cartilage suggest that
ATP, acting via purinergic pathways, may have beneﬁcial
effects on cartilage by stimulating proteoglycan synthesis
and inhibiting NO production10e14. In addition, it is reported
that a chronic treatment of human chondrocytes with
100e500-mM ATP induced the loss of glycosaminoglycans
but a single dose of 500-mM ATP increase proteoglycan
and collagen synthesis4. The reasons for this apparent
discrepancy concerning the role of ATP and purinergic
pathways are difﬁcult to establish due to the limited knowl-
edge concerning the expression, afﬁnities and functional
roles of purinergic receptors in cartilage. It is possible to
hypothesize that various ATP levels associated to the car-
tilage physiological and/or pathological conditions can lead
to the activation of different purinergic receptors subtypes.
In conclusion, for the ﬁrst time, the present study states
in a quantitative way the presence and the binding param-
eters of P2X1 and P2X3 purinergic receptors in bovine
chondrocytes. Binding and functional data on NO produc-
tion and PGE2 release conﬁrm a pivotal role of these puri-
nergic receptor subtypes in the inﬂammatory pathologies
linked to the articular cartilage. Novel purinergic ligands
could be potential targets for drug development in the
future in several cartilage pathological conditions.Conﬂict of interest
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